As expected, BRCA1 and BRCA2 PV rate nearly doubled in cases with a FH of PC nearly compared to sporadic subjects (3.6% vs. 1.7%), while it ranged from 1.7% to 15.8% in subjects with a personal or family history of breast/ovarian cancer (Table 2). This evidence concerns the gene BRCA2 and ovarian cancer.